EUCTR2019-001416-30-DE进行中（未招募）1 期
IDH2-Post-Allo-Trial: Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS following allogeneic blood stem cell transplantation
Heinrich-Heine-University Düsseldorf represented by the Coordinating Investigator0 个研究点目标入组 50 人开始时间: 2020年3月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with myeloid malignancy (AML, MDS and CMML) and known IDH2 mutation (IDH2 R172 or R140 mutation) at diagnosis prior to first allo-SCT
- •hematological CR after allo-SCT determined during screening period between day+25 and day +35
- •Hematopoietic recovery after transplantation indicated by an absolute neutrophil count of at least 1.000/microliter and platelet count of at least 50.000/microliter
- •no previous therapy with Enasidenib or any other IDH2 inhibitor
- •ECOG performance status = 2 at study entry (s. Appendix)
- •no active, steroid refractory GvHD treated with additional systemic immunosuppression within 4 weeks before inclusion
- •no uncontrolled infection at inclusion
- •Understand and voluntarily sign an informed consent form.
- •Age =18 years at the time of signing the informed consent form.
- •Able to adhere to the study visit schedule and other protocol requirements.
- •Female of childbearing potential (FCBP) must:
- •Understand that Enasidenib can cause embryo-fetal harm when administered to a pregnant woman
- •Agree to have a medically supervised pregnancy test prior to starting of Enasidenib
- •Use effective contraception during treatment with Enasidenib and for at least 2 months after the last dose
- •Coadministration of Enasidenib may increase or decrease the concentrations of combined hormonal contraceptives
- •Avoid becoming pregnant while receiving Enasidenib
- •Notify her study doctor immediately if there is a risk of pregnancy
- •Agree to abstain from breastfeeding during study participation and for at least 30 days after study drug discontinuation
- •Understand that Enasidenib may impair fertility in females of reproductive potential and this effect may be not reversible
- •Males must:
- •Understand that Enasidenib can cause embryo-fetal harm
- •Use effective contraception during treatment with Enasidenib and for at least 2 months after the last dose of Enasidenib if engaged in sexual activity with a pregnant female or a female with childbearing potential
- •Agree to notify the investigator immediately, if pregnancy or a positive pregnancy test occurs in his partner during study participation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •Any evidence of hematological relapse of the underlying IDH2-mutated myeloid malignancy (AML, MDS and CMML) determined during screening period until start of treatment
- •Any previous prophylactic therapy given within the interval between allo-SCT and screening period
- •Patients with myeloid malignancy (AML, MDS and CMML) and known IDH2 mutation (IDH2 R172 or R140 mutation) after second allo-SCT
- •Active, steroid refractory GvHD treated with additional requiring systemic immunosuppression within the last 4 weeks
- •Uncontrolled infection
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- •Pregnant or lactating females
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- •Impaired renal function (GFR < 30 ml/min)
- •Impaired hepatic function, as follows:primar
- •Aspartate aminotransferase =3 x ULN or Alanine aminotransferase (ALT) =3 x ULN or
- •Total bilirubin =3 x ULN or
- •Alkaline Phosphatase =3 x ULN
- •Known hypersensitivity to Enasidenib or any other component of the treatment
- •Prior history of malignancy other than AML, MDS or CMML (except basal and squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for =3 years
- •Concurrent use of other anti-cancer agents or treatments
- •Known positive for HIV or infectious hepatitis, type A, B or C
- •Participation in another study with ongoing use of unlicensed investigational product from 28 days before study enrollment until the end of the study (in cases where the investigational product has an unusually long half-life (e.g. antibodies), the interval until study enrollment must be at least five times the plasma half-life of the investigational product)
研究者
相似试验
进行中（未招募）
2 期
IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCTLeukemia, Myeloid, AcuteMyelodysplastic SyndromesIDH2 Gene MutationIDH2 R172IDH2 R140Chronic Myelomonocytic LeukemiaNCT04522895Heinrich-Heine University, Duesseldorf50
已完成
1 期
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaNCT05441514City of Hope Medical Center3
招募中
2 期
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromeBlasts 20-30 Percent of Bone Marrow Nucleated CellsIDH2 Gene MutationMyelodysplastic Syndrome With Excess BlastsRecurrent High Risk Myelodysplastic SyndromeRefractory High Risk Myelodysplastic SyndromeAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaNCT03383575M.D. Anderson Cancer Center63
招募中
2 期
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationAcute Bilineal LeukemiaAcute Biphenotypic LeukemiaIDH2 Gene MutationRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic LeukemiaNCT03683433M.D. Anderson Cancer Center50
招募中
2 期
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)Myelodysplastic SyndromeNCT06577441National Cancer Institute (NCI)54